1. Indications:

Cabani (Capmatinib) 200 mg is indicated for the treatment of metastatic NSCLC in adult patients with mutations in the MET exon 14 skipping (METex14) gene.

2. Pharmacology:

Cabani (Capmatinib) 200 mg exerts its pharmacological effects by selectively inhibiting the activity of the MET receptor tyrosine kinase. MET plays a crucial role in various cellular processes, including cell proliferation, survival, and migration. By blocking MET signaling, Cabani inhibits the growth and spread of cancer cells harboring MET exon 14 skipping mutations.

3. Dosage and Administration:

The recommended dosage of Cabani (Capmatinib) 200 mg may vary depending on individual patient characteristics and treatment response. Typically, the prescribed dose is 400 mg taken orally twice daily, with or without food. Patients should follow the dosing schedule provided by their healthcare provider and adhere to the prescribed regimen.

4. Interaction:

Cabani (Capmatinib) 200 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Cabani.
• Proton pump inhibitors (PPIs): Concurrent use of PPIs may reduce the absorption of Cabani, potentially decreasing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to minimize the risk of potential interactions.

5. Side Effects:

Common side effects associated with Cabani (Capmatinib) 200 mg may include:

• Peripheral edema
• Nausea
• Vomiting
• Fatigue
• Decreased appetite
• Increased blood creatinine levels

Patients should report any persistent or bothersome side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Cabani (Capmatinib) 200 mg, patients should be aware of the following precautions:

• Cabani may cause interstitial lung disease (ILD) or pneumonitis, which can be fatal. Patients should be monitored for respiratory symptoms and undergo regular imaging studies during treatment.
• Liver function abnormalities, including hepatotoxicity, have been reported with Cabani. Liver function tests should be performed before starting treatment and periodically thereafter.
• Women of childbearing potential should use effective contraception during treatment with Cabani, as it may cause fetal harm.

7. Overdose Effects:

In case of overdose with Cabani (Capmatinib) 200 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Cabani overdose, and patients should seek immediate medical attention if overdose is suspected.